Sprint Bioscience AB (publ) (STO:SPRINT)
Sweden · Delayed Price · Currency is SEK 2.850
-0.010 (-0.35%)
Sep 22, 2026, 5:24 PM CET
Sprint Bioscience AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 139.15 | 167.17 | 65.64 | 50.49 | 0.08 | 35.11 |
Other Revenue | 0.22 | 0.22 | 0.5 | 1.2 | - | -0.09 |
| 139.36 | 167.39 | 66.14 | 51.69 | 0.08 | 35.03 | |
Revenue Growth | 133.86% | 153.07% | 27.97% | 62171.08% | -99.76% | 82.48% |
Cost of Revenue | 7.39 | 13.08 | 28.34 | 8.7 | 12.93 | 10.44 |
Gross Profit | 131.98 | 154.31 | 37.8 | 42.99 | -12.85 | 24.59 |
Selling, General & Admin | 52.46 | 55.69 | 56.28 | 45.07 | 47.44 | 49.47 |
Other Operating Expenses | -0.47 | - | -0.67 | -1.21 | -0.29 | - |
Operating Expenses | 53.08 | 56.76 | 56.57 | 44.31 | 47.77 | 50.06 |
Operating Income | 78.9 | 97.55 | -18.77 | -1.32 | -60.62 | -25.47 |
Interest Expense | - | -0.42 | -0.04 | - | -0 | -0.27 |
Interest & Investment Income | 3.21 | 0.65 | 1.32 | 0.79 | - | - |
Currency Exchange Gain (Loss) | -6.04 | -6.04 | -0.79 | 0.09 | 0.45 | 0.69 |
Other Non Operating Income (Expenses) | -0.42 | - | -0 | - | -0 | -0.04 |
EBT Excluding Unusual Items | 75.65 | 91.74 | -18.28 | -0.44 | -60.17 | -25.08 |
Pretax Income | 75.65 | 91.74 | -18.28 | -0.44 | -60.17 | -25.08 |
Net Income | 75.65 | 91.74 | -18.28 | -0.44 | -60.17 | -25.08 |
Net Income to Common | 75.65 | 91.74 | -18.28 | -0.44 | -60.17 | -25.08 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 106 | 93 | 70 | 70 | 42 | 29 |
Shares Outstanding (Diluted) | 106 | 93 | 70 | 70 | 42 | 29 |
Shares Change | 41.49% | 32.63% | 0.01% | 65.98% | 45.85% | 71.85% |
EPS (Basic) | 0.72 | 0.99 | -0.26 | -0.01 | -1.43 | -0.87 |
EPS (Diluted) | 0.71 | 0.98 | -0.26 | -0.01 | -1.43 | -0.87 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 68.45 | 83.44 | -24.65 | 20.42 | -59.05 | -42.82 |
Free Cash Flow Per Share | 0.65 | 0.90 | -0.35 | 0.29 | -1.40 | -1.49 |
Gross Margin | 94.70% | 92.19% | 57.16% | 83.17% | - | 70.21% |
Operating Margin | 56.62% | 58.28% | -28.37% | -2.56% | -73031.32% | -72.70% |
Profit Margin | 54.29% | 54.81% | -27.63% | -0.85% | -72493.98% | -71.61% |
Free Cash Flow Margin | 49.11% | 49.85% | -37.27% | 39.50% | -71149.40% | -122.26% |
EBITDA | 79.99 | 98.62 | -17.81 | -0.88 | -60 | -24.88 |
EBITDA Margin | 57.40% | 58.92% | -26.93% | -1.70% | - | -71.02% |
D&A For EBITDA | 1.09 | 1.07 | 0.96 | 0.45 | 0.62 | 0.59 |
EBIT | 78.9 | 97.55 | -18.77 | -1.32 | -60.62 | -25.47 |
EBIT Margin | 56.62% | 58.28% | -28.37% | -2.56% | - | -72.70% |
Revenue as Reported | 139.21 | 167.65 | 67.44 | 54.32 | 0.45 | 35.07 |